# Beam Therapeutics Inc. (BEAM) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $29.66, market value $3.1 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Beam Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 19.6×**. Each dollar of revenue is priced at 19.6×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 2.8×**. The shares trade at 2.8× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -12.2%** (5-yr avg -8.5%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -242.3%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -57.2%**. The company reported a net loss over the last twelve months.
- **Return on equity: -6.5%**. Return on equity is negative because earnings are negative.
- **Return on assets: -5.8%**. Each dollar of assets produces -5.8% of profit.

## Growth
- **Revenue growth (1 yr): 120.0%** (3-yr 31.9%/yr, 5-yr 466.3%/yr). Revenue grew 120.0% over the last year, against 466.3% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 82.3%**. Earnings per share rose 82.3%, slower than revenue, so margins compressed.

## Financial health
- **Current ratio: 13.09** (quick 13.09). Current assets cover the next year's liabilities 13.09 times.
- **Altman Z-score: 8.93**. A Z-score of 8.93 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Beam Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (13 analysts). 13 analysts cover Beam Therapeutics Inc.; the consensus is strong_buy, with an average price target of $52.15 (+76% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 60.0%** (YTD 7.0%, 3-mo 0.9%). The shares are up 60.0% over twelve months including dividends.
- **From 52-week high: -22.5%** (53.2% above the low). Trading 22% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 54**. An RSI of 54 is neutral.
- **Beta (1 yr): 2.14** (volatility 75%). Beta of 2.14 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=BEAM · Page: https://foliofundamentals.com/stocks/beam

Not investment advice.